Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (235)	6/8/2007 12:15:18 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 507

In current issue of Kiplinger's magazine they have interiew with Bill Miller(Legg,Mason), the top stock picker in beating the S&P averages until losing out for the first time last year when he didn't. Anyway, one of his current picks in (MANN). His justification is that their "inhaler" will be smaller than (NKTRs) and he expects their market share to be in the billions. IMO Miller is barking up the wrong tree...it isn't the size that caused NKTRs problems, it's doctors having concerns about the safety of long term use of a inhaled drug.

To: tuck who wrote (235)	6/21/2007 1:56:37 PM
From: tuck	Respond to of 507

Notable Calls out with a blurb from a diabetes newsletter writer via Barrons online, suggesting that the safest investments in the space are with companies with products out: notablecalls.blogspot.com Cheers, Tuck

To: tuck who wrote (235)	6/21/2007 1:57:04 PM
From: tuck	Respond to of 507

Notable Calls out with a blurb from a diabetes newsletter writer via Barrons online, suggesting that the safest investments in the space are with companies with products out, including Nektar: notablecalls.blogspot.com Cheers, Tuck